Cormark upgraded shares of Curaleaf (OTCMKTS:CURLF – Free Report) from a hold rating to a moderate buy rating in a research report report published on Monday morning, Zacks.com reports. Cormark also issued estimates for Curaleaf’s FY2024 earnings at ($0.25) EPS and FY2025 earnings at ($0.18) EPS.
Separately, Needham & Company LLC reissued a buy rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th.
Get Our Latest Report on Curaleaf
Curaleaf Stock Performance
Curaleaf (OTCMKTS:CURLF – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.43% and a negative net margin of 20.29%. The company had revenue of $342.29 million during the quarter, compared to the consensus estimate of $344.57 million. On average, equities analysts forecast that Curaleaf will post -0.21 earnings per share for the current year.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
See Also
- Five stocks we like better than Curaleaf
- What Are Dividend Champions? How to Invest in the Champions
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Jeff Brown’s Exegesis AI Stock Picks
- The Significance of Brokerage Rankings in Stock Selection
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.